Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Top Cited Papers
- 20 August 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 15 (10), 1090-1099
- https://doi.org/10.1016/s1470-2045(14)70335-3
Abstract
No abstract availableKeywords
Funding Information
- Pharmacyclics Inc, Cancer Prevention and Research Institute of Texas, Leukemia & Lymphoma Society, the National Cancer Institute (grant P30 CA016672)
- MD Anderson Cancer Center (grant CA016672)
This publication has 37 references indexed in Scilit:
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage PropertiesThe Journal of Immunology, 2013
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaBlood, 2011
- The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study GroupJournal of Clinical Oncology, 2007
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005